Paying You to Decline: The Altria Dividend Dilemma

Altria stock (NYSE: MO) declined 5% following a Q4 earnings miss. While revenue (net of excise taxes) beat expectations at $5.08 billion versus the $5.02 billion estimate, the adjusted EPS of $1.30 missed the $1.32 consensus. The stock sold off because investors know earnings quality matters more than revenue surprises in tobacco. Furthermore, the company showed significant market share losses in its oral tobacco segment.

So, should you buy or sell Altria stock after the recent fall? Before we answer this, if you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 105% since its inception. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics. Separately, see – IBM Proves Old Tech Can Win At New AI.

Photo by Hans on Pixabay

What’s the margin story here? The GAAP operating margin collapsed from 56.4% in Q4 2024 to 30% in Q4 2025, largely due to a $1.3 billion non-cash impairment charge, related to its e-vapor business. The company is spending heavily on smoke-free product development and dealing with increased costs across the business. On an adjusted basis, the operating margin stood at 60.4%, down 80 bps y-o-y.

See, for a mature tobacco company, margin is everything. Altria’s business model is predicated on pricing power offsetting volume declines in combustibles. The company generated $20.91 billion in trailing twelve-month revenue—essentially flat with three years ago. Volume growth of 2.8% annualized over five years is anemic. This isn’t a growth story; it’s a cash generation story. And when margins compress this severely, the entire thesis gets questioned.

What about the 2026 guidance? Full-year adjusted EPS guidance of $5.56-$5.72 (midpoint $5.64) represents just 2.5-5.5% growth from 2025’s $5.42. That’s barely keeping pace with inflation. The company expects growth weighted to the second half, driven by increased cigarette import/export activity. But here’s the assumption risk: guidance assumes limited impact from illicit enforcement efforts, and that NJOY ACE doesn’t return to market in 2026.

So, is Altria stock expensive? Not really. If anything, the valuation looks attractive on paper. At roughly $60 per share, Altria trades at just 11x trailing earnings with a 7.2% dividend yield. The company returned $8 billion to shareholders in 2025 through dividends and buybacks. It repurchased 17.1 million shares at an average price of $58.50, deploying $1 billion of its $2 billion authorization. Another $1 billion remains for 2026. For the complete ranking, visit Buybacks & Dividends Ranking.

Now, the 11x multiple is much lower than the stock’s last five-year average figure of 16x. And there are a few positives as well to look forward to. The smoke-free transition is the real story. FDA authorization of six on! PLUS nicotine pouch products was a regulatory win, expanding the legal portfolio. The company distributed Proper Wild energy products to over 25,000 stores in 2025. But smoke-free products still contribute minimally to revenue and earnings. The core Marlboro cigarette business dominates financials. Although we are updating our $58 price estimate to account for the latest earnings, we anticipate minimal upside. Recent headwinds justify a more conservative valuation multiple at this stage.

What’s the competitive position? Altria owns the largest U.S. cigarette market share through Marlboro, but faces structural headwinds. Cigarette volumes declined 6% annually from 2019 to 2024 in the U.S. market—faster than the global 1% decline. The company has pricing power in a mature market, but volume erosion is accelerating. The on! pouch business is growing, but from a tiny base and facing intense competition.

Here’s what matters for investors: Are you comfortable owning a declining business that pays you 7%+ annually while it declines? That’s the Altria proposition. The stock trades at 11x earnings with a massive yield, but earnings growth is minimal. The smoke-free transformation is happening too slowly to offset combustible declines. Leadership transition (CEO Billy Gifford retiring May 2026, Sal Mancuso taking over) adds uncertainty.

The value proposition is clear—collect a big dividend while hoping smoke-free products eventually drive growth. For income investors who can tolerate a slow decline, the 7%+ yield offers compensation. For growth investors, there’s nothing here except slight undervaluation.

Remember, investing in a single stock without comprehensive analysis can be risky. Consider the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark (combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to produce strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks provided a responsive way to make the most of upbeat market conditions while limiting losses when markets head south, as detailed in RV Portfolio performance metrics.

Invest with Trefis Market-Beating Portfolios

See all Trefis Price Estimates